Eli Lilly cuts insulin prices after years of outrage
Enlarge / Advocates with T1Internationals New York, New Jersey, and Connecticut Chapters held a vigil on September 5, 2019, outside of Eli Lilly's offices honoring those who have lost their lives due to the high cost of insulin and demand lower insulin prices. (credit: Getty | Erik McGregor)
Pharmaceutical giant Eli Lilly, one of the country's leading insulin makers, announced Wednesday that it will slash its high list prices for some of its insulins and will immediately offer programs to limit out-of-pocket costs to $35 per month for people with commercial insurance as well as those who are uninsured.
The price cap matches the one set by the federal government for Medicare, which went into effect this year via the Inflation Reduction Act.
While Lilly's announcement comes just two months after enactment of the government's $35 cap, it follows years of blistering outrage over the skyrocketing prices of insulin in the US, widely seen as price gouging.